Zacks Investment Research upgraded shares of Trinity Biotech PLC (NASDAQ:TRIB) from a hold rating to a buy rating in a research report report published on Tuesday morning. The brokerage currently has $6.75 price objective on the stock.

According to Zacks, “Trinity Biotech plc, headquartered in Bray, the Republic of Ireland, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market worldwide. The company provides two haemostasis product lines, Biopool and Amax, comprising test kits and instrumentation used for the detection of blood disorders. These products are used to detect autoimmune, infectious and sexually transmitted diseases, diabetes and disorders of the blood, liver and intestine. The Company is also a provider of raw materials to the life sciences industry. It also engages in the provision of engineering, financial, and management services, as well as in trading business. Trinity Biotech sells its products through its sales force, as well as through a network of distributors and strategic partners. “

Separately, ValuEngine downgraded shares of Trinity Biotech PLC from a hold rating to a sell rating in a research report on Friday, June 2nd.

Trinity Biotech PLC (NASDAQ:TRIB) opened at 5.86 on Tuesday. The firm’s 50 day moving average price is $5.88 and its 200-day moving average price is $5.91. The firm’s market cap is $128.02 million. Trinity Biotech PLC has a one year low of $5.20 and a one year high of $13.68.

Trinity Biotech PLC (NASDAQ:TRIB) last posted its quarterly earnings results on Thursday, July 20th. The company reported $0.03 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.06 by $0.03. Trinity Biotech PLC had a negative net margin of 100.45% and a positive return on equity of 5.54%. The company had revenue of $25.45 million for the quarter, compared to analyst estimates of $24.83 million. Equities analysts predict that Trinity Biotech PLC will post $0.27 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Trinity Biotech PLC (NASDAQ:TRIB) Stock Rating Upgraded by Zacks Investment Research” was first published by Watch List News and is the property of of Watch List News. If you are accessing this article on another domain, it was stolen and republished in violation of U.S. & international copyright law. The original version of this article can be viewed at https://www.watchlistnews.com/trinity-biotech-plc-nasdaqtrib-stock-rating-upgraded-by-zacks-investment-research/1461254.html.

Several hedge funds and other institutional investors have recently modified their holdings of TRIB. Sawtooth Solutions LLC bought a new position in shares of Trinity Biotech PLC during the first quarter valued at about $103,000. GSA Capital Partners LLP bought a new position in shares of Trinity Biotech PLC during the fourth quarter valued at about $170,000. Wedbush Securities Inc. increased its position in shares of Trinity Biotech PLC by 122.3% in the first quarter. Wedbush Securities Inc. now owns 29,350 shares of the company’s stock valued at $175,000 after buying an additional 16,150 shares in the last quarter. Nine Chapters Capital Management LLC bought a new position in shares of Trinity Biotech PLC during the first quarter valued at about $183,000. Finally, Acadian Asset Management LLC bought a new position in shares of Trinity Biotech PLC during the first quarter valued at about $286,000. Hedge funds and other institutional investors own 66.30% of the company’s stock.

Trinity Biotech PLC Company Profile

Trinity Biotech plc (Trinity Biotech) develops, acquires, manufactures and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market. The Company’s products are used to detect autoimmune, infectious and sexually transmitted diseases, diabetes, and disorders of the liver and intestine.

Get a free copy of the Zacks research report on Trinity Biotech PLC (TRIB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Trinity Biotech PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trinity Biotech PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.